Alpha Layer / Signal Explorer

Signal Explorer

10-K · 10-Q · 8-K · last 6 months · ← back to feed

Clear ×
FIBROGEN INC FGEN

Showing 10-K, 10-Q & 8-K from the last 6 months. Need full history or all form types?

Aug 31, 2026 8-K 6 signals fired
Core
Lead Asset Progress Indication Expansion Clinical Hold
Other
Liquidity Position Snapshot Disclosed Interim Data Positive Expanded Access Program Active
Aug 13, 2026 10-Q 40 signals fired · top 15
Core
Regulatory Designation Only Clinical Trial Result
Other
Capital Raising Uncertainty Disclosed Fast Track Designation Received Orphan Status Granted Financing Activities Cash Flow Disclosure Fast Track Granted Reimbursement Price Pressure Risk Net Loss Reported Nasdaq Minimum Bid Price Delisting Notice Quarterly Tax Provision Benefit Disclosure Cybersecurity Breach Reputational Harm Disclosure Breakthrough Therapy Granted Sga Expense Comparison Disclosed
Biotech Risk
Orphan Drug Designation
Aug 13, 2026 8-K 16 signals fired · top 15
Core
Clinical Trial Result Lead Asset Progress Clinical Hold Combination Therapy Mentioned
Other
Interim Data Positive Publication Positive Fast Track Granted Kol Endorsement Liquidity Position Snapshot Disclosed Fast Track Designation Received Fda Aligned Enrollment Ahead Of Schedule Protocol Amended
Biotech Risk
Crl Received Clinical Hold Active
May 12, 2026 10-Q 44 signals fired · top 15
Core
Regulatory Designation Only
Other
Non Employee Director Compensation Disclosed Capital Raising Uncertainty Disclosed Anti Takeover Provision Disclosure Cash Flow Statement Investing Activities Sga Expense Comparison Disclosed Net Loss Reported Fast Track Designation Received Financing Activities Cash Flow Disclosure Orphan Status Granted Nyse Listing Disclosure Fast Track Granted Nasdaq Minimum Bid Price Delisting Notice Reimbursement Price Pressure Risk
Biotech Risk
Orphan Drug Designation
May 11, 2026 8-K 20 signals fired · top 15
Other
Net Loss Reported Interim Data Positive Expanded Access Program Active Publication Positive Enrollment Ahead Of Schedule Fda Aligned Checkpoint Inhibitor Program Kol Endorsement
Core
Clinical Trial Result Lead Asset Progress Combination Therapy Mentioned Clinical Hold Indication Expansion
Biotech Risk
Clinical Hold Active Crl Received
Apr 9, 2026 8-K 1 signal fired
Other
Nasdaq Minimum Bid Price Delisting Notice
Mar 16, 2026 10-K 94 signals fired · top 15
Other
Nol Carryforward Expiration Disclosure Competition Disclosure Change Of Control Definition Rsu Psu Vesting Schedule Disclosed Nol Tax Credit Carryforward Reverse Stock Split Effected Share Withholding Tax Settlement Headcount Disclosure Standard Equity Award Plan Types Enumerated Public Float Disclosure Sga Expense Comparison Disclosed Fast Track Designation Received Net Loss Reported
Core
Regulatory Designation Only Secondary Endpoint Mentioned
Mar 16, 2026 8-K 1 signal fired
Other
Net Loss Reported